Findings

What do systematic reviews say?

137 questions · 143 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 15 · 10.5%GRADE not reported 0 · 0%Very low 25 · 17.5%Low 75 · 52.4%Moderate 28 · 19.6%High 0 · 0%

Mycophenolate mofetil vs cyclophosphamide

Kidney function · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mycophenolate mofetil vs cyclophosphamide

Dialysis · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1 [0.14, 6.9]
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Relapse · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.8 [1, 3.22]
1 study · 127 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Remission · adults with renal vasculitis

Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.17 [1.01, 1.35]
3 studies · 216 participants
Moderate

Mycophenolate mofetil vs cyclophosphamide

Serious adverse events · adults with renal vasculitis

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Infection · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.27 [0.75, 2.16]
3 studies · 216 participants
Moderate

Azathioprine vs cyclophosphamide

Death (all causes) · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in death (median compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.77 [0.35, 1.72]
1 study · 144 participants
Moderate

Azathioprine vs cyclophosphamide

Kidney function · adults with renal vasculitis for maintenance therapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azathioprine vs cyclophosphamide

Dialysis · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in dialysis (median compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.65 [0.57, 4.79]
1 study · 144 participants
Moderate

Azathioprine vs cyclophosphamide

Relapse · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in relapse at 18 months compared with cyclophosphamide (moderate certainty).

2 findings from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.13 [0.51, 2.5]
1 study · 144 participants
Moderate
Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.46 [1, 2.14]
1 study · 144 participants
Moderate

Azathioprine vs cyclophosphamide

Serious adverse events · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.18 [0.45, 3.07]
1 study · 144 participants
Moderate

Azathioprine vs cyclophosphamide

Infections · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in infections compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.03 [0.51, 2.06]
1 study · 144 participants
Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children

It is very uncertain whether calcineurin inhibitor changes treatment response at 3 to 6 months: partial remission compared with IV cyclophosphamide (very low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.68 [0.43, 6.56]
2 studies · 156 participants
Very low

Calcineurin inhibitor vs IV cyclophosphamide

Adverse events: treatment failure (non response, serious infection, persistently elevated creatinine) at 6 months · idiopathic steroid‐resistant nephrotic syndrome in children

Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.32 [0.18, 0.58]
1 study · 124 participants
Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Discontinuation of medication due to adverse events · idiopathic steroid‐resistant nephrotic syndrome in children

Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.2 [0.04, 0.86]
1 study · 131 participants
Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Adverse events: serious infections · idiopathic steroid‐resistant nephrotic syndrome in children

Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.49 [0.16, 1.56]
1 study · 131 participants
Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Adverse events: death · idiopathic steroid‐resistant nephrotic syndrome in children

Calcineurin inhibitor showed no clear difference in adverse events: death compared with IV cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.92]
1 study · 131 participants
Low

IV vs oral cyclophosphamide

Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in complete remission compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.58 [0.65, 3.85]
2 studies · 61 participants
Low

IV vs oral cyclophosphamide

Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in partial remission compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1 [0.15, 6.55]
1 study · 50 participants
Low

IV vs oral cyclophosphamide

Remission · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.75 [0.19, 3.01]
1 study · 50 participants
Low